Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Public-Knowledge Based Applications Appropriate for Levonorgestrel, Methylprednisolone Sodium Succinate
January 20, 2014
- Mr Jo of EAD Criticizes Low Price Settlement Rates at Public Hospitals, Warns of Possible Reduction in Medical Fees
January 20, 2014
- PFSB Orders Distribution of Blue Letter on Bayer Yakuhin’s Dysmenorrhea Treatment YAZ Combination Tablets
January 20, 2014
- More Manpower, Knowledge Necessary for Giving New Drugs World’s First Approval: PMDA Chief Executive
January 17, 2014
- Chuikyo Approves General Proposal on Next Medical Fee Revision, Postpones Decision on Divided Dispensing
January 17, 2014
- Varicella, Adult Pneumococcal Vaccines to Join Japan’s Routine Immunization Program in October
January 16, 2014
- PMDA Posts RMPs for Rheumatoid Arthritis Treatment Iguratimod
January 16, 2014
- PFSB Calls for Revision of Package Inserts for Diabetes Drugs Including Lyxumia
January 15, 2014
- PAFSC’s First Committee to Review Second SGLT-2 Inhibitor Dapagliflozin on Jan 24
January 15, 2014
- MHLW Begins Probe into Suspected Data-Tampering of J-ADNI Project
January 15, 2014
- MHLW to Decide Measures by March 2014 to Improve Price Settlement Rates: Ministry Official
January 14, 2014
- Diovan Scandal Could Undermine Confidence in Clinical Studies: Minister Tamura
January 14, 2014
- MHLW Proposes that Medical Institutions Clarify in Invoices that Consumption Tax Is Included in Drug Prices
January 14, 2014
- Did Novartis Employees “Willfully” Use Rigged Data in Diovan Ads? Statute of Limitations Will Pose Hurdles to Chase Key Figure
January 10, 2014
- MHLW Seeks Criminal Charges against Novartis over Suspected PAL Violations, Diovan Ads Allegedly Misleading
January 10, 2014
- MHLW Files Criminal Complaint against Novartis over Diovan Ads
January 9, 2014
- Guidance on Companion Diagnostics Calls for Inclusion of Biomarker-Negative Subjects in Clinical Studies
January 8, 2014
- MHLW Adds Precaution for Driving in Package Inserts of Donepezil and Other Drugs
January 8, 2014
- MHLW to File Criminal Complaint against Novartis Jan. 8
January 8, 2014
- MHLW Economic Affairs Official Says Shakeout in Generic Sphere “Inevitable”
January 7, 2014
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…